After an early career as a professional musician, Dr. Steven Mickelsen decided to tackle medicine, specializing in electrophysiology. He later developed into a serial medical device entrepreneur with a focus on pulse field ablation (PFA) technology. His success with Farapulse revolutionized cardiac care and was acquired by Boston Scientific. Now, Dr. Mickelsen is the CEO of Field Medical, developing next-generation PFA solutions to address an unmet need in treating ventricular arrhythmias.
As a CEO, your primary roles are to secure funding and steer the company on the right path – something that’s easier said than done. For that, Dr. Mickelsen stresses the importance of experience. A seasoned CEO that has "done it before," can provide investors with realistic projections about costs and timelines, establishing trust and confidence in their leadership.
However, this doesn’t mean you should fret if you’re a green entrepreneur. If that’s the case, surround yourself with advisors or seasoned team members, people whom you can trust with financial and strategic decisions.
The other equally important thing is to be adaptable and prepared for the long haul. You need to be able to make critical adjustments as circumstances evolve, all while keeping the ultimate goal in sight.
And finally, don’t obsess over equity. Maintaining ownership is important, yes, but you need to understand that investors take significant risks. "You're asking people and firms to take incredible risks with their resources. No matter how good your idea is, you have to give them something for that," says Dr. Mickelsen.
The long and short of the matter is that while experience is invaluable, you can be successful in medtech with the right mindset. Understand that this is a long-term game that requires adaptability, be realistic about fundraising expectations, and take an upfront approach with investors about potential challenges.
When you’re passionate about improving patient outcomes, it resonates with investors and motivates your team, especially during challenging times. In Dr. Mickelsen’s’s words, “You should not have the expectation of holding on to 50% of your company, for example. Maybe that happens in Silicon Valley. In medtech, the real goal is to have a successful technology that's needed by physicians and deserved by patients. If we can bring that forward and our investors can come out on top, then it's a win-win."